Use the interactive world map to choose key health indicators from Health at a Glance 2009.
English, , 287kb
The aim of these guidelines is to propose a harmonised approach for the collection and analysis of biotechnology research and development (R&D) statistics in the government and higher education sectors.
This paper reports on the progress in the research and development of the set of patient safety indicators developed by the Health Care Quality Indicators project.
Overweight and obesity rates have been increasing relentlessly over recent decades in all industrialised countries, as well as in many lower income countries.
English, , 280kb
This presentation was given by Valérie Paris, Administrator, Health Division, OECD, at the Forum Économie Santé 2009, Les Échos Conférences, on 18 November 2009.
This book reviews how the emergence of pharmacogenetics will impact the efficiency of pharmaceutical R&D and improve healthcare decision making and clinical care. It discusses what policies need to change in order for the public to reap the benefits from advances in diagnostic genetic testin
The ability to effectively use these vast amounts of knowledge will depend in part on the bringing together of different strands of information, data and biological materials within human biobanks and genetic research databases (HBGRDs).
English, , 81kb
Written Statement to Ministers’ Round Table. David Morgan, Administrator, Health Division, OECD. Medical Tourism and Global Health Congress, Los Angeles, October 26th-28th, 2009.
English, Excel, 376kb
The United States spent 16% of its national income (GDP) on health in 2007, which is by far, the highest share in the OECD. This presentation was given by Mark Pearson, Head of OECD Health Division, to the U.S Senate Special Committee on Aging.
Slovak, Excel, 1,115kb
Slovak translation of Health Working Paper No. 28: "Pharmaceutical Pricing and Reimbursement Policies in Sweden", by Pierre Moïse and Elizabeth Docteur.